title: A GG allele of 3'-side AKT1 SNP is associated with decreased AKT1 activation and better prognosis of gastric cancer.
abstract: OBJECTIVE
  v-akt Murine thymoma viral oncogene homolog (AKT) pathway is critically involved in cancer cell growth, invasion, and survival. We examined the correlation between the genetic variations in molecules of AKT pathway and clinical outcomes of gastric cancer.
  
  
  METHODS
  Six single nucleotide polymorphisms (SNPs) located in the four core genes of AKT pathway, namely the PIK3CA, PTEN, AKT1, and mTOR, were determined in 221 patients with stage T2 and T3 gastric cancer. Additionally, the activation of AKT1 in gastric cancer tissues was examined by immunostaining. The correlation between SNPs, AKT activation, and the progress of gastric cancer was analyzed after an average of 51-month follow-up.
  
  
  RESULTS
  The overall recurrence and survival rate in this study group were 54.8 and 46.6 %, respectively. The recurrence rate was reduced 30.4 %, and the survival rate was increased 33.7 % in patients with GG allele of a 3'-side AKT1 SNP (rs2498804). Significantly, GG allele was associated with lower AKT1 activation in gastric cancer tissues. On the contrary, CC allele of PTEN (rs701848) was associated with the increased risk of recurrence (hazard ratio [HR] 2.06, 95 % CI 1.19-3.58) and patient death (HR 2.01, 95 % CI 1.15-3.53).
  
  
  CONCLUSIONS
  The genetic variants in the PI3K/PTEN/AKT especially the GG allele in 3' side of AKT1 are closely related to clinical outcomes of gastric cancer.
authors.affiliation: Department of Experimental Medicine, Fuzhou General Hospital (Dongfang Hospital), Clinical College of Fujian Medical University, 156 North Xi-er Huan Road, Fuzhou, 350025, Fujian, China.
authors.forename: Xiaoting
authors.initials: X
authors.lastname: Wang
authors.forename: Youdong
authors.initials: Y
authors.lastname: Lin
authors.forename: Fenghua
authors.initials: F
authors.lastname: Lan
authors.forename: Yinghao
authors.initials: Y
authors.lastname: Yu
authors.forename: Xuenong
authors.initials: X
authors.lastname: Ouyang
authors.forename: Xuzhou
authors.initials: X
authors.lastname: Wang
authors.forename: Qiaojia
authors.initials: Q
authors.lastname: Huang
authors.forename: Lie
authors.initials: L
authors.lastname: Wang
authors.forename: Jianming
authors.initials: J
authors.lastname: Tan
authors.forename: Feng
authors.initials: F
authors.lastname: Zheng
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D001483:Base Sequence; D001665:Binding Sites; D058534:Class I Phosphatidylinositol 3-Kinases; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004789:Enzyme Activation; D005260:Female; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D035683:MicroRNAs / Q000235:genetics; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000201:enzymology / Q000235:genetics* / Q000401:mortality / Q000517:prevention & control; D051059:PTEN Phosphohydrolase / Q000235:genetics; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics* / Q000378:metabolism; D013274:Stomach Neoplasms / Q000201:enzymology / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D016896:Treatment Outcome
chemical_list: C534451:MIRN20a microRNA, human; D035683:MicroRNAs; D019869:Phosphatidylinositol 3-Kinases; D058534:Class I Phosphatidylinositol 3-Kinases; C484760:PIK3CA protein, human; C494918:AKT1 protein, human; D051057:Proto-Oncogene Proteins c-akt; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human
references.citation: Gastric Cancer. 2007;10(1):45-51
references.pmid: 17334718
references.citation: Clin Cancer Res. 2013 Nov 15;19(22):6252-60
references.pmid: 24077347
references.citation: Nature. 2006 May 25;441(7092):424-30
references.pmid: 16724053
references.citation: Nat Rev Cancer. 2002 Jul;2(7):489-501
references.pmid: 12094235
references.citation: J Pathol. 2012 Aug;227(4):481-9
references.pmid: 22430898
references.citation: Cancer Cell. 2003 Oct;4(4):257-62
references.pmid: 14585353
references.citation: Cell Signal. 2002 May;14(5):381-95
references.pmid: 11882383
references.citation: BMC Med Genomics. 2011 Dec 02;4:82
references.pmid: 22133303
references.citation: JAMA. 2010 May 5;303(17):1729-37
references.pmid: 20442389
references.citation: Int J Cancer. 2003 Apr 10;104(3):318-27
references.pmid: 12569555
references.citation: Annu Rev Pathol. 2009;4:127-50
references.pmid: 18767981
references.citation: Carcinogenesis. 2010 Aug;31(8):1387-91
references.pmid: 20530239
references.citation: N Engl J Med. 2007 Nov 1;357(18):1810-20
references.pmid: 17978289
references.citation: Helicobacter. 2013 Sep;18 Suppl 1:28-33
references.pmid: 24011242
references.citation: Nat Rev Drug Discov. 2005 Dec;4(12):988-1004
references.pmid: 16341064
references.citation: Oncogene. 2008 Sep 18;27(41):5497-510
references.pmid: 18794884
references.citation: Nat Genet. 2012 May;44(5):570-4
references.pmid: 22484628
references.citation: Adv Cancer Res. 2005;94:29-86
references.pmid: 16095999
references.citation: Leukemia. 2011 Jul;25(7):1064-79
references.pmid: 21436840
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: J Clin Oncol. 2009 Feb 20;27(6):857-71
references.pmid: 19164214
references.citation: Int J Cancer. 2011 Oct 15;129(8):1872-80
references.pmid: 21154810
references.citation: Int J Cancer. 2005 Nov 10;117(3):376-80
references.pmid: 15900596
references.citation: Clin Cancer Res. 2013 Apr 15;19(8):2154-62
references.pmid: 23459718
references.citation: J Biol Chem. 2011 Dec 9;286(49):42211-42220
references.pmid: 21979951
references.citation: N Engl J Med. 2006 Jul 6;355(1):11-20
references.pmid: 16822992
references.citation: Clin Cancer Res. 2012 Jul 1;18(13):3705-13
references.pmid: 22577058
references.citation: Lung Cancer. 2011 Jan;71(1):82-8
references.pmid: 20447721
references.citation: BMC Cancer. 2013 Feb 01;13:43
references.pmid: 23374220